Melasma remains one of the most challenging pigmentary disorders in aesthetic dermatology. Chronic, recurrent, and particularly prevalent in women and individuals with darker skin tones, it often resists conventional therapies.
A recent systematic review highlights cysteamine as a promising, well-tolerated depigmenting agent offering meaningful clinical improvement with minimal adverse effects.
Clinical Evidence Supporting Cysteamine Efficacy and Safety
A recent systematic review analyzing clinical studies from the past decade confirms that cysteamine is an effective and well-tolerated option for treating melasma.
Across multiple trials, patients experienced meaningful improvements in pigmentation severity, with visible reductions in dark patches and overall skin discoloration.
Importantly, the treatment demonstrated a strong safety profile, with only mild and temporary skin reactions reported.
These findings position cysteamine as a promising alternative to more aggressive depigmenting therapies.
A New Approach to Pigmentation Management
The growing interest in cysteamine reflects a broader shift in aesthetic dermatology toward safer, biologically balanced approaches to pigmentation management.
Rather than aggressively bleaching the skin, modern strategies focus on regulating pigment production while preserving skin health and barrier integrity.
For chronic conditions like melasma, long-term stability and tolerability are just as important as visible results.
This evolution aligns with a new standard of care centered on intelligent, sustainable skin correction rather than short-term suppression.
LOUNA Perspective: Functional and Regenerative Correction
Cysteamine’s favorable safety and efficacy profile aligns with LOUNA’s philosophy of functional correction over aggressive intervention, reinforcing the importance of biologically aligned skin longevity strategies.
LOUNA integrates advanced cosmeceuticals and regenerative science to support intelligent pigmentation management and long-term skin health.
Title: The efficacy of cysteamine as a melasma therapy: a systematic review of trial studies.
Authors: Kusumawardani A, Octarica SG, Dewi AK, Sambodo SL, Utama RFD, Adjie SP
Published in: PMID 2025, Dec